^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tofacitinib

    i
    Other names: CP-690,550, CP-690550, CP690550
    Company:
    Generic mfg.
    Drug class:
    JAK inhibitor
    Related drugs:
    7d
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco | Initiation date: Jan 2026 --> Aug 2026
    Trial initiation date
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • cyclosporine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn) • chloroquine phosphate
    7d
    ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)
    P=N/A, N=102, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    tofacitinib
    8d
    TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review. (PubMed, Int J Tuberc Lung Dis)
    Risk of bias was assessed using ROBIS.RESULTSAnti-TNF monoclonal antibodies (infliximab, adalimumab) were consistently associated with the highest TB risk (odds ratio commonly 3-5), with greater proportions of disseminated/extra-pulmonary disease compared to etanercept...JAK inhibitors (notably tofacitinib) conferred geographically variable risk, higher in intermediate/high-burden countries. Immune checkpoint inhibitors, especially PD-1/PD-L1 agents, were linked to TB incidence far above background rates.CONCLUSIONTB risk varies markedly across biologic and targeted agents. Risk-based TB infection screening and tailored prophylaxis beyond anti-TNF therapy are warranted, particularly in endemic regions..
    Journal
    |
    IL6 (Interleukin 6) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
    |
    tofacitinib
    9d
    SMART-JIA: Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (clinicaltrials.gov)
    P3, N=400, Recruiting, Duke University | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial primary completion date
    |
    tofacitinib • Orencia (abatacept)
    10d
    A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL (2024-516570-30-00)
    P1/2, N=12, Not yet recruiting, Centre Hospitalier De Versailles
    New P1/2 trial
    |
    Venclexta (venetoclax) • everolimus • azacitidine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • tofacitinib
    19d
    TARA: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (clinicaltrials.gov)
    P3, N=459, Active, not recruiting, Hangzhou Highlightll Pharmaceutical Co., Ltd | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Jan 2026
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    tofacitinib
    21d
    TARA: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (clinicaltrials.gov)
    P3, N=459, Active, not recruiting, Hangzhou Highlightll Pharmaceutical Co., Ltd | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2028 | Trial primary completion date: Feb 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Head-to-Head
    |
    tofacitinib
    21d
    MISSION-1: Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1 (clinicaltrials.gov)
    P2, N=92, Recruiting, University of Colorado, Denver
    New P2 trial
    |
    tofacitinib
    23d
    Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center. (PubMed, Ther Adv Musculoskelet Dis)
    Case 1 (PsA): Long-standing disease (24 years) failed optimized adalimumab; following DTT, disease activity in psoriatic arthritis (DAPSA) score improved from high disease activity (36) to low disease activity (8). Our real-world findings demonstrate improved disease control and safety when monotherapy fails. Future prospective studies are essential to optimize the selection, dosing, and long-term safety of DTT.
    Journal
    |
    CRP (C-reactive protein)
    |
    tofacitinib
    27d
    EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)
    P=N/A, N=4000, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)
    29d
    Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis (clinicaltrials.gov)
    P=N/A, N=130, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Apr 2030 --> Dec 2029 | Trial primary completion date: Apr 2030 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    methotrexate • tofacitinib
    1m
    Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series. (PubMed, RMD Open)
    Conventional synthetic disease-modifying antirheumatic drugs and tumour necrosis factor inhibitors were ineffective or poorly tolerated, whereas tofacitinib and upadacitinib induced rapid and durable improvement across articular, cutaneous, vascular and pulmonary domains. These observations support a role for JAK-STAT signalling in MRH and suggest JAK inhibition as a rational therapeutic option in refractory multisystem disease.
    Journal
    |
    CD68 (CD68 Molecule)
    |
    tofacitinib